Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

423.12 -8.88 (-2.06%)
Streaming Delayed Price Updated: 3:50 PM EDT, May 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
61 62 Next >
$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Large Cap BIopharmaceuticals Overview
As a defensive play healthcare is weighted at about 12% of the S&P 500. 
Via Talk Markets
Topics Stocks
Exposures US Equities
This Is What Whales Are Betting On Vertex Pharmaceuticals
Via Benzinga
3 No-Brainer Stocks to Buy in June
Now is the time to invest in these great stocks. 
Via The Motley Fool
5 Top Stocks to Buy in June
This medley of growth, value, and income stocks is poised to thrive long-term, even if the stock market sells off this summer. 
Via The Motley Fool
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Eli Lilly is in a buy zone, while rival Novo Nordisk forged a lower entry. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Analyst Expectations For Vertex Pharmaceuticals's Future
Via Benzinga
While growth is established for NASDAQ:VRTX, the stock's valuation remains reasonable.
NASDAQ:VRTX is showing decent growth, but is still valued reasonably. 
Via Chartmill
2 Biotech Stocks to Buy in May
You could buy these in any month, really. 
Via The Motley Fool
A Very Bullish Reversal Produces A Huge Batch Of Actionable Stocks
It is very hard to get excited about what I'm seeing in the stock market because things have not been the way I've wanted them to be. In this video, I want to show you something as we look at a monthly... 
Via Talk Markets
Vertex Stock Recently Hit All-Time High, Leads 8 Top Performers New To IBD Stock Lists
Vertex stock was one of a select group of eight that made it onto IBD top-stocks lists Friday. The big pharma is near its all-time high. 
Via Investor's Business Daily
Should Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals?
Vertex might not present a clear and present danger to Abbott and DexCom but could present a clear future threat. 
Via The Motley Fool
Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic
Arcturus Therapeutics' early Phase 1 results show ARCT-032 is safe and well-tolerated, with promising improvements in lung function. 
Via Benzinga
Got $500? 3 Pharma Stocks to Buy and Hold Forever
These players might even beat the market when the conditions are right. 
Via The Motley Fool
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity
Via Benzinga
Should you consider NASDAQ:VRTX for quality investing?
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) Exhibits Quality Stock Traits. Here's Why. 
Via Chartmill
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know
Via Benzinga
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Shares of the growing biotech company have doubled in three years. 
Via The Motley Fool
3 High-Flying Stocks That Could Soar Even More
The momentum should continue for Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals. 
Via The Motley Fool
SLB, First Solar And 2 Other Stocks Insiders Are Selling
Via Benzinga
Walmart, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
Walmart Inc. reported a "really strong" quarter, with e-commerce sales surging 21%. Adjusted EPS was 60 cents. 
Via Benzinga
The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now
With interest cuts on the horizon, it's a prime time to consider these high-risk-high-reward biotech stocks to buy. 
Via InvestorPlace
Vertex to Participate in Upcoming June Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating
On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier. 
Via Investor's Business Daily
Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So.
How much would you pay for a stock that might earn $25 a year in six years? 
Via The Motley Fool
Jennifer Schneider Elected to Vertex Board of Directors
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades'
Pfizer is looking to build on the success of its COVID-19 vaccine rollout by introducing a direct-to-consumer medicines platform. 
Via Benzinga
Exposures COVID-19
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79. 
Via Investor's Business Daily
3 Cheap Biotech Stocks to Buy Now: May 2024
Many of these cheap biotech stocks are on their way to achieving FDA approval for their drugs to enter the market. 
Via InvestorPlace
Exposures Product Safety
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
61 62 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.